Developing biotherapeutics,
biobetters, and innovative products
We develop an innovative human erythropoietin-based neurotherapeutic to meet the needs of millions of people around the world who suffer from central nervous systems conditions like Parkinson´s disease, Alzheimer´s disease, multiple sclerosis, stroke, among others; for which, nowadays there is no effective treatment.
Human erythropoietin (hEPO) is a widely used biotherapeutic for anemia treatment because it stimulates red blood cells production. Besides, hEPO has neuroprotective and neuroplastic activity. Nevertheless, when it is used as a neuropharmaceutical in patients who do not suffer from anemia, it causes erythropoietic activity-associated side effects. Thus, from BioSynaptica, we have developed hEPO-based neurotherapeutic candidates through an innovative idea, to block its undesired effect but preserving its neurotherapeutic potentiality.
Socia co-fundadora
BioSynaptica S.A.
Socio co-fundador
BioSynaptica S.A.
Socio co-fundador
BioSynaptica S.A.
Socio co-fundador
BioSynaptica S.A.